Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study

dc.contributor.authorShoji, Jun
dc.contributor.authorGoggins, William C.
dc.contributor.authorWellen, Jason R.
dc.contributor.authorCunningham, Patrick N.
dc.contributor.authorJohnston, Olwyn
dc.contributor.authorChang, Shirley S.
dc.contributor.authorSolez, Kim
dc.contributor.authorSantos, Vicki
dc.contributor.authorLarson, Tami J.
dc.contributor.authorTakeuchi, Masahiro
dc.contributor.authorWang, Xuegong
dc.contributor.departmentSurgery, School of Medicine
dc.date.accessioned2024-09-20T10:38:24Z
dc.date.available2024-09-20T10:38:24Z
dc.date.issued2024
dc.description.abstractBackground: Focal segmental glomerulosclerosis (FSGS) is a common cause of end-stage kidney disease and frequently recurs after kidney transplantation. Recurrent FSGS (rFSGS) is associated with poor allograft and patient outcomes. Bleselumab, a fully human immunoglobulin G4 anti-CD40 antagonistic monoclonal antibody, disrupts CD40-related processes in FSGS, potentially preventing rFSGS. Methods: A phase 2a, randomized, multicenter, open-label study of adult recipients (aged ≥18 y) of a living or deceased donor kidney transplant with a history of biopsy-proven primary FSGS. The study assessed the efficacy of bleselumab combined with tacrolimus and corticosteroids as maintenance immunosuppression in the prevention of rFSGS >12 mo posttransplantation, versus standard of care (SOC) comprising tacrolimus, mycophenolate mofetil, and corticosteroids. All patients received basiliximab induction. The primary endpoint was rFSGS, defined as proteinuria (protein-creatinine ratio ≥3.0 g/g) with death, graft loss, or loss to follow-up imputed as rFSGS, through 3 mo posttransplant. Results: Sixty-three patients were followed for 12 mo posttransplantation. Relative decrease in rFSGS occurrence through 3 mo with bleselumab versus SOC was 40.7% (95% confidence interval, -89.8 to 26.8; P = 0.37; absolute decrease 12.7% [95% confidence interval, -34.5 to 9.0]). Central-blinded biopsy review found relative (absolute) decreases in rFSGS of 10.9% (3.9%), 17.0% (6.2%), and 20.5% (7.5%) at 3, 6, and 12 mo posttransplant, respectively; these differences were not statistically significant. Adverse events were similar for both treatments. No deaths occurred during the study. Conclusions: In at-risk kidney transplant recipients, bleselumab numerically reduced proteinuria occurrence versus SOC, but no notable difference in occurrence of biopsy-proven rFSGS was observed.
dc.eprint.versionFinal published version
dc.identifier.citationShoji J, Goggins WC, Wellen JR, et al. Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation. 2024;108(8):1782-1792. doi:10.1097/TP.0000000000004985
dc.identifier.urihttps://hdl.handle.net/1805/43457
dc.language.isoen_US
dc.publisherWolters Kluwer
dc.relation.isversionof10.1097/TP.0000000000004985
dc.relation.journalTransplantation
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourcePMC
dc.subjectAdrenal cortex hormones
dc.subjectImmunosuppressive agents
dc.subjectTacrolimus
dc.subjectChronic kidney disease
dc.titleEfficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Shoji2024Efficacy-CCBYNCND.pdf
Size:
981.55 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.04 KB
Format:
Item-specific license agreed upon to submission
Description: